Results 101 to 110 of about 10,168 (235)

FAPα+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD‐L1 and T Cell Senescence

open access: yesAdvanced Science, EarlyView.
Fibroblast activation protein alpha‐positive (FAPα+) macrophages, a distinct subset of multiple myeloma (MM)‐associated macrophages, drive immune evasion in MM through multi‐faceted mechanisms. FAPα physically interacts with vimentin (VIM) and triggers its phosphorylation at the S72 residue, which in turn induces PD‐L1 transcription. Additionally, FAPα
Huiyao Gu   +15 more
wiley   +1 more source

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

open access: yesAdvanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance   +17 more
wiley   +1 more source

Bufalin Inhibits the PI3K/AKT Pathway by Targeting GTF3C4 to Impede Breast Cancer Progression

open access: yesAdvanced Science, EarlyView.
Mechanisms of Bufalin‐Mediated Intervention in Breast Cancer. ABSTRACT Breast cancer incidence is rising globally, presenting challenges such as treatment side effects and drug resistance. Bufalin is a bufadienolides compound with potential anti‐cancer effects. This study shows that bufalin inhibits malignant proliferation of MDA‐MB‐231 and MCF‐7 cells
Siyu Guo   +15 more
wiley   +1 more source

Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade

open access: yesJournal for ImmunoTherapy of Cancer
Background Immune checkpoint blockade (ICB) has made remarkable achievements, but newly identified armored and cold tumors cannot respond to ICB therapy. The high prevalence of concomitant medications has huge impact on immunotherapeutic responses, but the clinical effects on the therapeutic outcome of armored and ...
Jie Mei   +14 more
openaire   +3 more sources

Strawberry Notch 1 Acts as a Transcriptional Regulator Driving Oncogenic Programs in Liver Carcinogenesis

open access: yesAdvanced Science, EarlyView.
This study reports that SBNO1 protein is upregulated in several cancer entities. SBNO1 protein interacts with the basal transcription factor TFIID via TAF4, enabling its recruitment to transcription start sites and the modulation of target gene expression.
Sarah Fritzsche   +21 more
wiley   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

open access: yesAdvanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao   +16 more
wiley   +1 more source

Dynamics of the Mammalian Placental Metabolome in Placentogenesis and Embryonic Development

open access: yesAdvanced Science, EarlyView.
This study identifies three metabolic stages (E8.5, E9.5–10.5, E11.5–14.5) and two transition periods (E8.5–9.5, E10.5–11.5) in mouse placental development. NAD(H) emerges as a key dynamic metabolite that enhances embryonic growth through accelerated segmentation and increased proliferation of mouse embryonic stem cell (mESC)‐induced presomitic ...
Gang Chen   +11 more
wiley   +1 more source

A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses

open access: yesiScience
Summary: Mesenchymal stromal cells (MSCs) have been modified via genetic or pharmacological engineering into potent antigen-presenting cells-like capable of priming responding CD8 T cells.
Marina Pereira Gonçalves   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy